126 related articles for article (PubMed ID: 616929)
1. Animal models for tardive dyskinesia: effects of thioridazine.
Sayers AC; Bürki HR; Ruch W; Asper H
Pharmakopsychiatr Neuropsychopharmakol; 1977 Sep; 10(5):291-5. PubMed ID: 616929
[TBL] [Abstract][Full Text] [Related]
2. The pathophysiology of tardive dyskinesia.
Klawans HL; Carvey P; Tanner CM; Goetz CG
J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):38-41. PubMed ID: 2858479
[TBL] [Abstract][Full Text] [Related]
3. Effect of scopolamine on the efflux of dopamine and its metabolites after clozapine, haloperidol or thioridazine.
Meltzer HY; Chai BL; Thompson PA; Yamamoto BK
J Pharmacol Exp Ther; 1994 Mar; 268(3):1452-61. PubMed ID: 8138957
[TBL] [Abstract][Full Text] [Related]
4. Classification of neuroleptics: implications for tardive dyskinesia.
Christensen AV
Pol J Pharmacol Pharm; 1985; 37(3):295-309. PubMed ID: 2866499
[TBL] [Abstract][Full Text] [Related]
5. Antagonism of dopamine supersensitivity by estrogen: neurochemical studies in an animal model of tardive dyskinesia.
Gordon JH; Diamond BI
Biol Psychiatry; 1981 Apr; 16(4):365-71. PubMed ID: 7194695
[TBL] [Abstract][Full Text] [Related]
6. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
Hu XT; White FJ
Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
[TBL] [Abstract][Full Text] [Related]
7. Differential liabilities of haloperidol and thioridazine for inducing apomorphine hypersensitivity.
De Veaugh-Geiss J; Devanand DP; Carey RJ
Biol Psychiatry; 1982 Nov; 17(11):1289-301. PubMed ID: 6891268
[TBL] [Abstract][Full Text] [Related]
8. Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia.
Rogoza RM; Fairfax DF; Henry P; N-Marandi S; Khan RF; Gupta SK; Mishra RK
Synapse; 2004 Dec; 54(3):156-63. PubMed ID: 15452862
[TBL] [Abstract][Full Text] [Related]
9. [Effects of anticholinergics and clozapine on the activation of the striatal dopaminergic system in the rat by haloperidol. Pharmacological findings (author's transl)].
Sayers AC; Bürki HR
Arzneimittelforschung; 1976; 26(6):1092-3. PubMed ID: 989384
[TBL] [Abstract][Full Text] [Related]
10. Comparative antidopaminergic properties of thioridazine, mesoridazine and sulforidazine on the corpus striatum.
Niedzwiecki DM; Cubeddu LX; Mailman RB
J Pharmacol Exp Ther; 1989 Jul; 250(1):117-25. PubMed ID: 2746491
[TBL] [Abstract][Full Text] [Related]
11. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
Carta AR; Frau L; Pinna A; Pontis S; Simola N; Schintu N; Morelli M
Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422
[TBL] [Abstract][Full Text] [Related]
12. Relative selectivity of 6,7-dihydroxy-2-dimethylaminotetralin, N-n-propyl-3-(3-hydroxyphenyl)piperidine, N-n-propylnorapomorphine and pergolide as agonists at striatal dopamine autoreceptors and postsynaptic dopamine receptors.
Claustre Y; Fage D; Zivkovic B; Scatton B
J Pharmacol Exp Ther; 1985 Feb; 232(2):519-25. PubMed ID: 2857197
[TBL] [Abstract][Full Text] [Related]
13. Effects of chronic administration of neuroleptic and anticholinergic agents on densities of D2 dopamine and muscarinic cholinergic receptors in rat striatum.
Boyson SJ; McGonigle P; Luthin GR; Wolfe BB; Molinoff PB
J Pharmacol Exp Ther; 1988 Mar; 244(3):987-93. PubMed ID: 2908050
[TBL] [Abstract][Full Text] [Related]
14. Greater potency of mesoridazine and sulforidazine compared with the parent compound, thioridazine, on striatal dopamine autoreceptors.
Niedzwiecki DM; Mailman RB; Cubeddu LX
J Pharmacol Exp Ther; 1984 Mar; 228(3):636-9. PubMed ID: 6707914
[TBL] [Abstract][Full Text] [Related]
15. Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias.
Delfino MA; Stefano AV; Ferrario JE; Taravini IR; Murer MG; Gershanik OS
Behav Brain Res; 2004 Jul; 152(2):297-306. PubMed ID: 15196797
[TBL] [Abstract][Full Text] [Related]
16. Phenytoin potentiation of neuroleptic-induced dyskinesias.
Sethi KD; Hitri A; Diamond BI
Mov Disord; 1990; 5(4):325-7. PubMed ID: 2147979
[TBL] [Abstract][Full Text] [Related]
17. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Hossain MA; Weiner N
J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
[TBL] [Abstract][Full Text] [Related]
18. Degree of selectivity of pergolide as an agonist at presynaptic versus postsynaptic dopamine receptors: implications for prevention or treatment of tardive dyskinesia.
Fuller RW; Clemens JA; Hynes MD
J Clin Psychopharmacol; 1982 Dec; 2(6):371-5. PubMed ID: 7174859
[TBL] [Abstract][Full Text] [Related]
19. Ergoline derivative LEK-8829-induced turning behavior in rats with unilateral striatal ibotenic acid lesions: interaction with bromocriptine.
Sprah L; Zivin M; Sket D
J Pharmacol Exp Ther; 1999 Mar; 288(3):1093-100. PubMed ID: 10027846
[TBL] [Abstract][Full Text] [Related]
20. Relationship between asymmetries in striatal dopamine release and the direction of amphetamine-induced rotation during the first week following a unilateral 6-OHDA lesion of the substantia nigra.
Robinson TE; Noordhoorn M; Chan EM; Mocsary Z; Camp DM; Whishaw IQ
Synapse; 1994 May; 17(1):16-25. PubMed ID: 8042143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
